Trained immunity offers a mechanistic bridge between IBD and cardiovascular injury
Inflammatory bowel disease IBD is no longer confined to the gut in clinical practice. Crohn’s disease and ulcerative colitis carry a cardiovascular burden that extends well beyond traditional risk scoring, with higher rates of myocardial infarction, heart failure, stroke, and venous thromboembolism seen even after conventional factors are accounted for. The biological explanation centers on immune memory inside the innate compartment: trained immunity reshapes monocytes, macrophages, and even bone marrow progenitors so they respond more aggressively to later vascular stressors.
This framework matters because it helps explain why cardiovascular risk persists in patients whose bowel symptoms appear controlled. Histologic inflammation can remain active beneath clinical remission, and that residual inflammatory tone appears to track with major adverse cardiovascular events. In bedside terms, the heart may remain exposed to inflammatory spillover long after the intestinal flare quiets.
Active intestinal inflammation amplifies vascular risk beyond standard factors
Epidemiologic data consistently place cardiovascular disease among the leading causes of morbidity and mortality in IBD. Risk is higher during active disease, and active IBD raises the risk of major adverse cardiovascular events by about 50% compared with remission. Histological inflammation independently predicts major adverse cardiovascular events and remains linked to myocardial infarction and heart failure even when symptoms improve. In practical terms, symptom control alone does not fully neutralize vascular risk.
Subtype-specific patterns are also striking. Crohn’s disease carries a stronger association with ischemic heart disease, while ulcerative colitis shows a more pronounced relationship with venous thromboembolism. Chinese cohorts have shown markedly increased ischemic heart disease risk in IBD, with peaks in young women, and Japanese ulcerative colitis cohorts show rising cumulative major adverse cardiovascular event incidence with age, with diabetes and atrial fibrillation contributing substantially. A Swedish nationwide cohort of 55,252 patients confirmed a doubled venous thromboembolism risk in IBD.
One sentence captures the clinical consequence: bowel inflammation can reprogram the coagulation system.
Microbial translocation and cytokine signaling drive disease-specific cardiovascular phenotypes
Crohn’s disease and ulcerative colitis appear to reach the heart through overlapping but not identical immunologic routes. In Crohn’s disease, NOD2 signaling is central; the principal Crohn’s susceptibility gene has been tied to worsened myocardial ischemia-reperfusion injury through JNK/p38 MAPK/NF-κB signaling, and NOD2 up-regulation has been detected in coronary atheroma lesions. In ulcerative colitis, barrier failure allows lipopolysaccharide LPS to move into the systemic circulation, where it binds TLR4 on monocytes and induces tissue factor expression, activating the extrinsic coagulation cascade.
That divergence helps explain why arterial and venous events do not rise in exactly the same way across IBD subtypes. It also places gut barrier failure at the center of extraintestinal disease. Tight junction loss, mucus thinning, and dysbiosis convert the intestine from a localized inflammatory site into a continuous source of immune stimulation.
Epigenetic memory in monocytes sustains inflammation after the flare
Trained immunity is not adaptive immunity in disguise. It is an innate program shaped by epigenetic and metabolic reprogramming, with persistent changes in histone marks, chromatin accessibility, and cellular fuel use. In this state, monocytes and macrophages become primed for exaggerated responses to later stimuli, including atherosclerotic triggers in the vascular wall. Bone marrow hematopoietic stem and progenitor cells can also acquire this memory, sustaining myeloid output long after the initial insult.
At the epigenetic level, enrichment of H3K4me3 and H3K27ac at pro-inflammatory promoters keeps genes such as TNF and IL6 ready for rapid transcription. At the metabolic level, trained cells shift toward aerobic glycolysis and increased glutaminolysis, with the mevalonate pathway supplying intermediates that reinforce inflammatory gene expression. Mitochondrial remodeling raises reactive oxygen species, activating the NLRP3 inflammasome and stabilizing HIF-1α, a feed-forward loop that supports endothelial dysfunction and myocardial injury.
Dysbiosis, barrier failure, and bone marrow reprogramming create a systemic inflammatory axis
The microbial signature of IBD is consistent and biologically coherent. Loss of short-chain fatty acid producing commensals such as Faecalibacterium prausnitzii, Roseburia, and Coprococcus combines with expansion of adherent-invasive Escherichia coli and Escherichia-Shigella. Short-chain fatty acids normally restrain inflammation through histone deacetylase inhibition; when those metabolites fall, the brake comes off pro-inflammatory transcription. Secondary bile acids with anti-inflammatory properties also decline, while primary bile acids rise and further disturb immune and metabolic signaling through FXR and TGR5 pathways.
The intestine then feeds the marrow. Microbial products that cross the impaired barrier stimulate circulating monocytes and Kupffer cells, while systemic cytokines such as TNF-α reach hematopoietic niches and bias progenitors toward myeloid differentiation. Single-cell and transcriptomic studies in ulcerative colitis have shown lactylation changes in hematopoietic stem and progenitor cells, supporting a metabolic-epigenetic mechanism for durable reprogramming. Once that process begins, the body produces more inflammatory monocytes, not fewer.
Monocyte phenotypes and biomarkers may help identify high-risk patients
Peripheral blood findings in IBD align with the trained immunity model. Monocytes from patients with IBD produce more TNF-α, IL-1β, and IL-6 after secondary stimulation than cells from healthy controls. Monocytosis correlates with disease severity and with outcomes such as hospitalization, surgery, and emergency department visits. Classical and intermediate monocyte subsets shift in distribution, and pro-inflammatory monocyte function increases in parallel with disease activity.
These changes may eventually support risk stratification, especially if combined with inflammatory markers such as C-reactive protein and fibrinogen. Elevated CRP and fibrinogen track with cardiovascular risk, and residual risk persists even when lipid values appear deceptively low. The so-called lipid paradox in IBD reflects more than cholesterol concentration; lipoprotein function, particle quality, and cytokine-driven vascular injury may matter more than the absolute LDL number.
Therapeutic translation will depend on whether immune memory can be reset
The review points toward two broad therapeutic goals: reduce intestinal inflammation early and interrupt the trained immunity program before it injures the vasculature. Deep remission may lower cardiovascular risk by reducing the inflammatory signals that keep monocytes and progenitors activated. Microbiota-targeted strategies may also help by restoring short-chain fatty acid production, reducing endotoxin translocation, and normalizing bile acid signaling.
Directly targeting trained immunity is an appealing concept, but clinical translation remains incomplete. The molecular pathways are well mapped, yet biomarkers that reliably capture trained immune states in routine practice are still lacking. The strongest immediate use of this framework may be clinical vigilance: patients with active disease, histologic inflammation, elevated inflammatory markers, or recurrent flares should not be viewed as having isolated intestinal pathology. Their cardiovascular system is part of the same inflammatory circuit.